Hormone Replacement Therapy Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, Segmented By Product (Estrogen & Progesterone Replacement Therapy, HGH Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Replacement Therapy, and Parathyroid Hormone Replacement), By Route of Administration (Oral, Parenteral, Transdermal, and Others), By Disease Ty

Global hormone replacement therapy (HRT) market is expected to rise at a high CAGR during the forecast period, 2024-2028. Growing prevalence of other hormonal imbalance disorders which are common among people of various developing countries in the world are expected to register a lucrative growth to global hormone replacement therapy market in the forecast period. Growth in global geriatric population and certain hormonal disorders such as andropause, hyperthyroidism, hypothyroidism, and others which are associated with people during their elder age are expected to propel the growth of hormone replacement therapy market across the world in the forecast period. Furthermore, improvement in worldwide healthcare infrastructure which are leading to innovations in hormone replacement therapy are further expected to register an impressive growth to global hormone replacement therapy market in the forecast period.

Hormone Replacement Therapy (HRT) is a medical treatment that involves replacing the hormones that are produced in lower quantities in the body especially after treatment of certain types of cancer and menopause in women. Various types of hormone replacement therapy that are commonly performed across the world includes estrogen-only therapy, combination therapy, transdermal therapy, and bioidentical hormone therapy.

The United States of America, Canada, Australia, and several European countries such as France, Italy, and Sweden account for highest number of hormone replacement therapies performed among their population in the forecast period. Several health conditions that can be efficiently managed by hormone replacement therapy in the human body comprise of menopause symptoms, osteoporosis, hypogonadism, gender dysphoria, endometriosis, and breast cancer.

Rising Prevalence of Hormonal Imbalance Disorders

. According to the report published by BMC on Reproductive Biology and Endocrinology in 2021, it has been observed that India stood at highest position for around 22.7% PCOS cases being diagnosed in the country, followed by 20% cases in Philippines, 15.9% cases in Australia, 13.7% cases in United Kingdom, 12.2% cases in United States of America, and so on.

Hormone Replacement Therapy involves taking synthetic hormones to replace the hormones that are not being produced adequately by the body. In case of polycystic ovary syndrome (PCOS), hormone replacement therapy is used to regulate menstrual cycles, reduce hair growth, and remove acne. Another common hormonal disorders which are prevailing people of every age group and gender worldwide are thyroid disorders such as hypothyroidism and hyperthyroidism. According to World Health Organization (WHO), around 750 million people are suffering from some form of thyroid disorder in the world. The prevalence of thyroid disorders increases with age which account for around 20% women over 60 years of age having some form of thyroid dysfunction. In some regions, such as Southeast Asia, Africa, and South America around 50% of people are diagnosed with iodine deficiency every year which leads to the development of goiter (enlarged thyroid gland) and hypothyroidism. Moreover, effective results in management of various hormonal disorders after hormone replacement therapy are expected to register an impressive growth of global hormone replacement therapy market in the forecast period.

According to the report published by Forth with Life in 2019, it has been observed that around 73% of people suffer from hot flushes during menopause followed by 63% of people suffering from drowsiness, 47% people from low concentration, 43% people from memory troubles, and so on.

Development of Healthcare Infrastructure

Recent Developments

• In June 2022, Halozyme Therapeutics, Inc.announced the commercial launch of TLANDO (testosterone undecanoate), an oral treatment indicated for testosteronereplacement therapy in adult males for conditions associated with a deficiencyor absence of endogenous testosterone.
• In February 2022,Pfizer Inc. and OPKO Health, Inc. announced that the European Commission hasgranted marketing authorization for the next-generation long-acting recombinanthuman growth hormone NGENLA, a once-weekly injection to treat children andadolescents from 3 years of age with growth disturbance due to insufficientsecretion of growth hormone.
• In May 2021,Myovant Sciences GmbH announced that it received approval from the U.S. FDA forits hormone therapy Myfembree as a treatment for uterine fibroid bleeding. Thedrug launched by Myovant will give direct competition to AbbVie with an addeddosing advantage.
• In April 2021,TherapeuticsMD, Inc. and Theramex announced that they received approval from theMedicines and Healthcare Products Regulatory Agency (MHRA) and Federal Agencyof Medicines and Health Products (FAMPH) for the use of BIJUVE in U.K and underBIJUVA trade name in Belgium. The capsule will be used as a hormone replacementtherapy.
• Allergen Plc wasprocured by AbbVie in 2020. It is going to grow the portfolio to oncology,immunology, neuroscience, and so forth.
• In December 2019,Pfizer, Inc. introduced a new drug known as Xtandi, which has received approvalfrom U.S. FDA. This Xtandi is a combination of anti-hormone therapy and helpsreduce cancer spreading. Pfizer completed the Weiss merger in December 2014,outpacing popular products such as Prempro and Premarin.
  
  

Market Segmentation

Market Players